-Laureate to Manufacture Tolerx's TRX518 Antibody
PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full-
service biopharmaceutical development and protein production company, today
announced that it has entered into a cGMP contract manufacturing agreement
with Tolerx, Inc., a biopharmaceutical company engaged in the discovery and
development of novel therapies for the treatment of immune-mediated
diseases. Under the agreement, Laureate will produce Tolerx's humanized
anti-GITR antibody known as TRX518, which is currently in development for
cancer and chronic viral indications. Details of the agreement were not
disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO)
"The partnership with Tolerx validates the progress we have made in
biomanufacturing and our commitment in helping our clients bring novel
therapies to the market," said Robert J. Broeze, Ph.D., President & Chief
Executive Officer of Laureate. "With our well established monoclonal
antibody experience, we will partner closely with the Tolerx team to help
them achieve their manufacturing objectives."
"Laureate Pharma has a proven track record in biopharmaceutical
manufacturing, including capabilities in both clinical and commercial-grade
materials," said Dr. Douglas J. Ringler, President and Chief Executive
Officer of Tolerx. "This agreement enables us to operationally leverage
Laureate's expertise and infrastructure while we seek to establish new
treatment paradigms in the immunology space."
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate
Pharma offers superior bioprocessing services that accelerate new products
from development through production. Laureate provides a wide range of
specialized services from process design and development to full-scale cGMP
production, purification, aseptic filling, testing, validation, analytical
services, and regulatory support. Laureate is focused on two active
segments of the biopharmaceutical industry: monoclonal antibodies and
recombinant protein products. For more information, contact Michael
Cavanaugh, Vice President Sales, Marketing, and Business Development at
(609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.
About Tolerx
Tolerx is a biopharmaceutical company engaged in the discovery and
development of novel therapies for immune-mediated diseases. TRX518 is
directed to GITR and is in preclinical development for the treatment of
cancer and chronic viral diseases. TRX518 is thought to circumvent immune
system tolerance by inhibiting the suppressive activity of T regulatory
cells and extending the survival of T effector cells, thereby enhancing
responses to tumor and viral antigens. Tolerx also has two antibodies in
clinical development for the treatment of various autoimmune indications,
these are: otelixizumab, an anti-CD3 MAb that is being developed in
collaboration with GlaxoSmithKline and MTRX1011A a modified form of TRX1,
an anti-CD4 MAb that is being developed in collaboration with Genentech,
Inc. In addition to TRX518, Tolerx is also engaged in the preclinical
development of other antibodies that may shift or modulate the immune
system. For more information, please visit http://www.tolerx.com.
SOURCE Laureate Pharma, Inc.
 back to top
Related links:
http://www.laureatepharma.com
http://www.tolerx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Michael Cavanaugh, Vice President Sales,
Marketing, and Business Development, +1-609-919-3400,
info@laureatepharma.com
|
